1 week Ago By ABMN Staff
Danaher Co. ( NYSE:DHR – Free Report ) – Research analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Danaher in a report released on Tuesday, April 22nd. William Blair analyst M.
Larew now expects that the conglomerate will post earnings of $1.65 per share for the quarter, down from their prior estimate of $1.82.
The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. William Blair also issued estimates for Danaher’s Q2 2026 earnings at $1.
86 EPS, Q3 2026 earnings at $2.10 EPS, Q4 2026 earnings at $2.51 EPS and FY2026 earnings at $8.
56 EPS. Danaher ( NYSE:DHR – Get Free Report ) last issued its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.
88 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.26.
The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.58 billion.
Danaher had a net margin of 16.33% and a return on equity of 10.82%.
Get Our Latest Stock Analysis on Danaher Danaher Stock Up 0.4 % DHR stock opened at $197.37 on Thursday.
The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.
05. Danaher has a 12 month low of $171.00 and a 12 month high of $281.
70. The firm has a market capitalization of $141.06 billion, a PE ratio of 37.
38, a P/E/G ratio of 2.66 and a beta of 0.86.
The company’s 50 day simple moving average is $200.87 and its 200-day simple moving average is $224.58.
Danaher Increases Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 25th. Shareholders of record on Friday, March 28th were paid a dividend of $0.32 per share.
This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.
28 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend was Friday, March 28th.
Danaher’s payout ratio is currently 24.85%. Insider Transactions at Danaher In related news, SVP Brian W.
Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.
00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90.
The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link .
Company insiders own 11.10% of the company’s stock. Institutional Inflows and Outflows Hedge funds and other institutional investors have recently modified their holdings of the stock.
Alta Advisers Ltd raised its holdings in shares of Danaher by 46.9% during the 1st quarter. Alta Advisers Ltd now owns 3,133 shares of the conglomerate’s stock valued at $642,000 after buying an additional 1,000 shares during the period.
Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the first quarter valued at approximately $31,000. Smith Salley Wealth Management raised its stake in shares of Danaher by 15.5% during the first quarter.
Smith Salley Wealth Management now owns 1,488 shares of the conglomerate’s stock valued at $305,000 after purchasing an additional 200 shares during the period. Koshinski Asset Management Inc. lifted its position in shares of Danaher by 18.
2% during the first quarter. Koshinski Asset Management Inc. now owns 1,738 shares of the conglomerate’s stock worth $356,000 after purchasing an additional 267 shares in the last quarter.
Finally, Spinnaker Trust boosted its stake in shares of Danaher by 9.2% in the first quarter. Spinnaker Trust now owns 4,699 shares of the conglomerate’s stock valued at $963,000 after purchasing an additional 395 shares during the period.
Institutional investors and hedge funds own 79.05% of the company’s stock. About Danaher ( Get Free Report ) Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. Read More Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter .
.
